In this short video, the speaker outlines the FDA’s current reevaluation of injectable GHK‑Cu (a copper‑binding peptide) for several therapeutic areas: regenerative wound healing, dermal atrophy in elderly and steroid‑dependent patients, chronic obstructive pulmonary disease (COPD) with lung remodeling, and hair‑follicle restoration. The speaker shares a personal anecdote, saying they have been applying the peptide to their hairline and receiving plasma injections, and report being impressed with the results. The core of the discussion then shifts to safety concerns: potential copper overload, secondary zinc deficiency, and the theoretical risk that GHK‑Cu‑induced angiogenesis could nourish tumors. The speaker notes that these concerns are common across peptide therapeutics, but admits that the validity of the risks is uncertain and that no definitive data exist.
